Damora Therapeutics, Inc. (DMRA) company profile
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
About Damora Therapeutics
Pharmaceutical Preparations, SIC 2834
Damora Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on discovering and developing therapies for hematologic disorders. The company's pipeline centers on treatments for myeloproliferative neoplasms, which are chronic bone marrow disorders driven by myeloid cell proliferation. Its primary development programs include DMR-001, DMR-002, and DMR-003, which are monoclonal antibody candidates designed to selectively target mutant calreticulin. These investigational therapies aim to treat patients diagnosed with essential thrombocythemia and myelofibrosis.
The company operates in the United States and conducts its research and development programs through collaborative licensing arrangements. Its lead therapeutic candidates remain in preclinical development, with regulatory filings planned across multiple target indications. Damora Therapeutics maintains its principal executive offices in Waltham, Massachusetts.
Summary of the business section of Damora Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Damora Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 100 Fifth Avenue, Suite 700 02451
- Phone
- (781) 281-9020
- Website
- damoratx.com
- Employees
- 7, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark
Stock & identifiers
- Ticker
- DMRA
- Former tickers
- GLTO until Mar 10, 2026
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2020
- Shares outstanding
- 62M, Aug 7, 2026
- Public float
- $4.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 30, 2024
- SEC CIK
- 1800315
- CUSIP
- 36322Q206
- ISIN
- US36322Q2066
- FIGI
- BBG00XMLGWC5
- Share class FIGI
- BBG00XMLGWD4
- EIN
- 37-1957007
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 512,500 |
| Hans T. Schambye | Chief Executive Officer, Director | 4,682 |
| Garrett Winslow | General Counsel | 2,289 |
| Brian Burkavage | SVP, Finance | – |
| Sherwin Sattarzadeh | Chief Operating Officer | 190,376 |
| L. Becker Hewes | Chief Medical Officer | 264,629 |
| Lori Firmani | Chief Financial Officer | 931 |
| Matthew Kronmiller | EVP Strategy and CBO | – |
| Andrew Cheng | Director | – |
| Healthcare Fund II L.P. Fairmount | Director | 8,713,000 |
| Cameron Turtle | Director | – |
| Christopher W. Cain | Director | – |
| Peter Evan Harwin | Director | – |
| Funds Management LLC Fairmount | Director | – |
| Julianne Bruno | Director | 137,032 |
| Healthcare Co-Invest V. L.P. Fairmount | Director | – |
| Michael Landsittel | Director | – |
| David Shapiro | Director | – |
| Jayson Donald Alexander Dallas | Director | – |
| Amit Munshi | Director | 4,793 |
| Anne Prener | Director | – |
| Carl Goldfischer | Director | 1,049,055 |
| Amy B. Wechsler | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.30M | $2.13M | $708.98K | $128 | – |
| FY2024 | $1.43M | $1.23M | $759.67K | $26 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Hans T. Schambye, M.D., Ph.D. Former President and Chief Executive Officer | $547.52K | $678.59K | $73.68K | – | $1.30M | -9% |
| Lori Firmani Chief Financial Officer | $311.25K | $202.50K | $22.46K | $27.00K | $563.21K | +0% |
| Garrett Winslow General Counsel | $400.40K | $400.40K | $26.96K | $27.00K | $854.76K | -5% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 30, 2020
- Offer price
- $15.00
- Securities offered
- 5,666,667
- Gross proceeds
- $85.00M
- Exchange
- Nasdaq
- First trading day
- Oct 29, 2020
- First-day close
- $15.000.0%
- Lock-up ends (est.)
- Apr 27, 2021
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had seven full-time employees, including one who holds a Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 10, 2026 | Name change | Name changed from Galecto, Inc. to Damora Therapeutics, Inc. |
| Nov 10, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 7, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 2, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 30, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 23, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?